Maraviroc: A review of its use in the management of CCR5-Tropic HIV-1 infection

Drugs

Volumn 70, Issue 9, 2010, Pages 1189-1213

  Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; HIV infections; Maraviroc, general

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BILIRUBIN; CHEMOKINE RECEPTOR CCR5; CLARITHROMYCIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ETRAVIRINE; HYPERICUM PERFORATUM EXTRACT; IMMUNOGLOBULIN E; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RIFAMPICIN; RITONAVIR PLUS SAQUINAVIR; TELITHROMYCIN; TRIACYLGLYCEROL LIPASE;

ABDOMINAL DISTENSION; ABNORMAL DREAMING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; APPETITE DISORDER; ARTHROPATHY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BLOATING; BRONCHITIS; CHICKENPOX; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; EOSINOPHILIA; FEVER; FLATULENCE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER FUNCTION TEST; LIVER TOXICITY; NAIL DISEASE; NEOPLASM; NEUTROPHIL COUNT; NONHUMAN; PARESTHESIA; QT INTERVAL; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SLEEP DISORDER; SWEAT GLAND DISEASE; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CCR5; TREATMENT FAILURE; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD; VIRAL TROPISM; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953097279     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203940-000000000-00000     Document Type: Review

References (64)

1. http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf [Accessed 2010 May 23] Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf [Accessed 2010 May 23]
2. Hammer SM, Eron Jr JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel. JAMA 2008 Aug 6; 300 (5): 555-570
3. European AIDS Clinical Society. Guidelines for the clinical management and treatment of HIV-infected adults in Europe [online]. Available from URL: http://www.european aidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV- Infected-Adults.pdf [Accessed 2010 May 23]
4. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608
5. Moyle G, Gatell J, Perno CF, et al. Potential for new anti-retrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDS 2008 Jun; 22 (6): 459-471
6. Dau B, Holodniy M. Novel targets for antiretroviral ther-apy: clinical progress to date. Drugs 2009; 69 (1): 31-50
7. Boffito M, Abel S. A review of the clinical pharmacology of maraviroc: introduction. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 1-4
8. MacArthur RD, Novak RM. Reviews of anti-infective agents. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008 Jul 15; 47 (2): 236-241
9. Palani A, Tagat JR. Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. J Med Chem 2006; 49 (10): 2851-2857
10. Sierra S, Kaiser R, Thielen A, et al. Genotypic coreceptor analysis. Eur J Med Res 2007 Oct 15; 12 (9): 453-462
11. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008 Mar; 73 (3): 789-800
12. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pre-treatment CXCR4-using virus reservoir. J Virol 2006 May; 80 (10): 4909-4920
13. Sax PE. Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full? J Infect Dis 2010 Mar 15; 201: 797-799
14. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007 Mar; 81 (5): 2359-2371
15. European Medicines Agency. Celsentri (maraviroc): summary of product characteristics. Updated 2010 Jan 11 [online]. Available from URL: http://www.emea.europa.eu/human docs/PDFs/EPAR/celsentri/emea-combined-h811en. pdf [Accessed 2010 May 23]
16. Pfizer Inc. Selzentry (maraviroc) US prescribing information. Revised 11/2009 [online]. Available from URL: http://us.gsk.com/products/assets/us- selzentry.pdf [Accessed 2010 May 23]
17. Poveda E, Seclen E, Gonzalez M del M, et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009 May; 63 (5): 1006-1010
18. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008 Oct 2; 359 (14): 1429-1441
19. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010 Mar 15; 201: 803-813
20. Heera J, Ive M, Botes M. The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results [slide presentation TUAB103]. 5th International AIDS Society Conference on HIV Pathogenesis; 2009 Jul 19-22; Capetown
21. Heera J, Saag M, Ive P, et al. Virological correlates asso-ciated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients [abstract no. 40LB]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA) 22.
22. Carter NJ, Keating GM. Maraviroc. Drugs 2007; 67 (15): 2277-88; discussion 2289-2290
23. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 Nov; 49 (11): 4721-4732
24. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008 Oct 2; 359 (14): 1442-1455
25. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmaco-kinet 2009; 48 (4): 211-241
26. Soulie C, Malet I, Lambert-Niclot S, et al. Primary geno-typic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. AIDS 2008 Oct 18; 22 (16): 2212-2214
27. Castagna A, Biswas P, Beretta A, et al. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 2005; 65 (7): 879-904
28. Lewis M, Mori J, Simpson P, et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials [abstract no. 871]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
29. Mori J, Lewis M, Simpson P, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2 [abstract no. 10]. XVI International HIV Drug Resistance Workshop; 2007 Jun 12-16; Barbados
30. Lewis M, Simpson P, Xiting L, et al. Dual-tropic virus clones from patients enrolled in the MOTIVATE studies, may respond differently in vivo to maraviroc based on their V3 loop sequence [abstract no. 50]. Sixth European HIV Drug Resistance Workshop; 2008 Mar 26-28; Budapest
31. Vandekeckhove L, Verhofstede C, Vogelaers D. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother 2009 Jun; 63 (6): 1087-1096
32. Svicher V, Balestra E, Vandenbroucke I, et al. Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc [slide presentation]. 7th European HIV Drug Resistance Workshop; 2009 Mar 25-27; Stockholm
33. Garcia F, Chueca N, Alvarez M, et al. Low detection of non-CCR5 using strains by ultra deep sequencing does not compromise response to maraviroc containing regimen [abstract no. 22]. 8th European HIV Drug Resistance Workshop; 2010 Mar 17-19; Sorrento
34. Jubb B, Lewis M, Simpson P, et al. CCR5-tropic resistance to maraviroc is uncommon even among patients on functional maraviroc monotherapy or with ongoing low-level replication [abstract no. 639]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal (QC)
35. Saracino A, Monno L, Brindicci G, et al. Are the proposed env mutations actually associated with resistance to mar-aviroc? [letter]. J Acquir Immune Defic Syndr 2010 April 1; 53 (4): 550-552
36. Craig C, Heera J, Lewis M, et al. Mechanisms of virologic failure with maraviroc in treatment-naive HIV-infected patients through 96 weeks [abstract plus poster no. 536]. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-19; San Francisco (CA)
37. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase 3 studies MOTIVATE 1 and MOTIVATE 2 originates from a pre-existing minority of CXCR4-using virus [abstract no. 56 plus poster and oral presentation]. XVI International HIV Drug Resistance Workshop; 2007 Jun 12-16; Barbados
38. Sanders F, Wheeler JG, Myrand SP, et al. Effect of CCR5 locus polymorphisms on virologic response to maraviroc in antiretroviral-experienced CCR5-tropic individuals in MOTIVATE 1 and 2 [abstract no. P4.4/04]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, 51
39. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009 Aug 15; 51 (5): 546-553
40. Tiraboschi JM, Curto J, Niubo J, et al. Maraviroc levels in cerebrospinal fluid (CSF) and seminal plasma from HIV-infected patients [abstract plus poster no. 114]. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-19; San Francisco (CA)
41. Brown K, Patterson K, Malone S, et al. Antiretrovirals for prevention: maraviroc exposure in the semen and rectal tissue of healthy male volunteers after single and multiple dosing [abstract no. 85]. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-19; San Francisco (CA)
42. Yilmaz A, Watson V, Else L, et al. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009 Nov 27; 23 (18): 2537-2540
43. Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008 Oct; 66 (4): 498-507
44. Abel S, Russell D, Whitlock LA, et al. The effects of cotri-moxazole or tenofovir co-administration on the pharmaco-kinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 47-53 (Pubitemid 351366538)
45. Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 19-26 (Pubitemid 351366535)
46. Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and ralte-gravir. Br J Clin Pharmacol 2010 Jan; 69 (1): 51-57
47. Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 38-46 (Pubitemid 351366537)
48. Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 Apr; 65 Suppl. 1: 27-37
49. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in vire-mic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results from a phase 2b/3 study in the US and Canada [abstract no. 104bLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
50. Nelson M, Fatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results [abstract no. 104aLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
51. Hardy WD, Gulick R, Mayer HB, et al. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-I: 96-week combined analysis of the MOTIVATE 1 and 2 studies [oral presentation plus abstract no. O425]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
52. Ayoub A, Goodrich J, van der Ryst E, et al. Adverse event (AE) profile of maraviroc (MVC) in treatment-experienced (TE) patients infected with R5 HIV-1 [poster no. H-1264]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America-A Joint Meeting; 2008 October 25-28; Washington, DC
53. Ayoub A, Walmsley R, Campo R, et al. Incidence of ma-lignancies in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) +optimized background therapy (OBT): 96 week follow-up [abstract plus poster no. WEPEB246]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009 Jul 19-22; Cape Town
54. Dolin R. A new class of anti-HIV therapy and new chal-lenges. N Engl J Med 2008 Oct 2; 359 (14): 1509-1511
55. Soulie C, Fourati S, Lambert-Niclot S, et al. Factors asso-ciated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010 Apr; 65 (4): 749-751
56. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials in treatment-experienced subjects [abstract no. 800]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
57. Saag M, Goodrich J, Fatkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009 Jun 1; 199 (11): 1638-1647
58. Jones R, Gazzard B. The cost of antiretroviral drugs and influence on prescribing policies. Int J STD AIDS 2006; 17: 499-506
59. Kuehne FC, Chancellor J, Mollon P, et al. Modelling the cost-effectiveness of maraviroc for antiretroviral treatment-experienced individuals [abstract plus poster no. P10.4/02]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, 108
60. Chancellor JV, Kuehne FC, Mollon P, et al. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals [abstract no. IN3]. Value Health 2008 May 30; 11 (No.3): A24
61. Contreras-Hernandez I, Becker DL, Chancellor JV, et al. Cost-effectiveness of maraviroc for HIV in Mexico [abstract no. PIN35]. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2009 May 16-20; Orlando (FL), 116
62. Contreras-Hernandez I, Rely K, Mould-Quevedo J, et al. The economic impact of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico [abstract no. PIN36]. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2009 May 16-20; Orlando (FL), 116
63. Lekander I, Berg J, Christie A, et al. A cost-effectiveness analysis of maraviroc in treatment-experienced HIV patients in Scotland [abstract no. P315]. 9th International Congress on Drug Therapy in HIV Infection; 2008 Nov 9-13; Glasgow
64. Fatkenheuer G. Maraviroc: a viewpoint. Drugs 2007; 67: 2289-2290